Nucl Med Mol Imaging.  2019 Apr;53(2):96-101. 10.1007/s13139-019-00580-3.

Current Status and Growth of Nuclear Theranostics in Singapore

• Huang HL
• Tong AK
• Thang SP
• Yan SX
• Lam WW
• Loke KS
• Tang CY
• Cheng LT
• Ooi GS
• Low HC
• Magsombol
• Tham WY
• Goh CX
• Tan CJ
• Khor YM
• Zaheer S
• Bharadwaj
• Xie W
• Ng DC

• KMID: 2448096
• DOI: http://doi.org/10.1007/s13139-019-00580-3

Abstract

The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of "˜personalised' medicine. With the growth of theranostics, nuclear medicine as a specialty is uniquely poised to grow along with the ever-increasing number of concepts combining imaging and therapy. This special report summarises the status and growth of Theranostic Nuclear Medicine in Singapore.We will cover our experience with the use of radioiodine, radioiodinated metaiodobenzylguanidine, peptide receptor radionuclide therapy, prostate specific membrane antigen radioligand therapy, radium-223 and yttrium-90 selective internal radiation therapy.We also include a section on our radiopharmacy laboratory, crucial to our implementation of theranostic principles. Radionuclide theranostics has seen tremendous growth and we hope to be able to grow alongside to continue to serve the patients in Singapore and in the region.

Keyword

Theranostic; Singapore; Radioiodine; Lutetium; Yttrium; Radium

MeSH Terms

Hope
Humans
Lutetium
Membranes
Nuclear Medicine
Prostate
Radium
Receptors, Peptide
Singapore*
Theranostic Nanomedicine*
Yttrium
Lutetium
Radium
Receptors, Peptide
Yttrium